Screener
Cytokinetics CYTK Operating Lease Liabilities
Operating Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.
The source filing: Cytokinetics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:30 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338217
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Term loans, net | 248,202 | 246,384 |
| Convertible notes, net | 871,527 | 869,597 |
| Liabilities related to revenue participation right purchase agreements, net | 558,054 | 520,559 |
| Long-term operating lease liabilities | 102,426 | 107,970 |
| Liabilities related to RPI Transactions measured at fair value | 136,400 | 137,200 |
| Total liabilities | 2,098,038 | 2,084,162 |
| Commitments and contingencies | ||
| Stockholders' deficit |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Cytokinetics's operating lease liabilities?
- Cytokinetics (CYTK) reported operating lease liabilities of $102.43M in Q2 2026.
- How has Cytokinetics's operating lease liabilities changed year-over-year?
- Cytokinetics's operating lease liabilities decreased by 7.7% year-over-year, from $111.03M to $102.43M.
- What is the long-term trend for Cytokinetics's operating lease liabilities?
- Over 5 years (2020 to 2025), Cytokinetics's operating lease liabilities has grown at a 200.6% compound annual growth rate (CAGR), from $440K to $107.97M.
- What does operating lease liabilities mean?
- Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.
Ask your AI about Cytokinetics's operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude